Fezolinetant Guidelines and Emerging Data on Menopause and Liver Health

EP: 1.Overview of KNDy neurons

EP: 2.VMS Symptoms and Neurokinin Receptor Antagonists

EP: 3.Neurokinin and Estrogen Balance in Menopausal Hot Flashes for Primary Care

Now Viewing

EP: 4.Fezolinetant Guidelines and Emerging Data on Menopause and Liver Health

EP: 5.Molecular Comparison and Safety Profiles of Fezolinetant and Elinzanetant

EP: 6.Malignancy Risks of Neurokinin Receptor Antagonists

EP: 7.Guidance for PCPs: Streamlining Menopause Care

EP: 8.Nonestrogen Treatments for Menopause

EP: 9.VMS Treatment Guidelines

• Why was a warning about serious liver injury added to the prescribing information for fezolinetant? (ie, postmarketing case of drug-induced liver injury)

Note: Clarify that when fezolinetant first came out, it had guidelines for baseline liver testing. But in the past month, this was updated- discuss update and what this means for patients/ physicians.

• What baseline hepatic laboratory tests are recommended before patients start fezolinetant, and how often should they be monitored?
• What symptoms or clinical laboratory values indicate that fezolinetant should be discontinued?
• What are important discussion points to address patient concerns on liver health?